Nicox Reports Positive Results of Secondary Analyses from Phase 2 Trial Further Highlighting Potential of NCX 470 in Glaucoma
NCX 470 0.065% produced significantly superior intraocular pressure (IOP) lowering compared with latanoprost 0.005% in secondary analyses NCX 470 showed improved IOP lowering with each incremental concentration of NCX 470 tested, setting the stage for …